ConserV Says Its Vaccine R&D Is 'Aimed At The Next Pandemic’
Enters mRNA Pact with Belgium’s eTheRNA Targeting Highly Mutagenic Viruses
Executive Summary
ConserV CEO tells Scrip why the late-stage vaccine developer has entered an mRNA development pact with eTheRNA of Belgium and about the UK biotech’s hopes for finding a universal jab against the entire coronavirus family.
You may also be interested in...
Deal Watch: AI Specialist Biolojic Inks Diabetes Pact With Lilly, Autoimmune Tie-Up With Nektar
Plus deals involving AbbVie/Mitokinin, Roivant/Silicon Therapeutics, CASI/Cleave Therapeutics, Tallac/ALX Oncology, AgeX/LyGenesis, Chinook/Evotec and more.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.